Literature DB >> 32622445

Cardiovascular Risk Factors and Atherosclerotic Cardiovascular Events Among Incident Cases of Systemic Sclerosis: Results From a Population-Based Cohort (1980-2016).

Reto D Kurmann1, Avneek S Sandhu2, Cynthia S Crowson3, Eric L Matteson3, Thomas G Osborn2, Kenneth J Warrington2, Rekha Mankad4, Ashima Makol5.   

Abstract

OBJECTIVE: To characterize cardiovascular (CV) risk factors and outcomes among incident cases of systemic sclerosis (SSc) in a population-based cohort.
METHODS: Medical records of patients with SSc diagnosed in Olmsted County, Minnesota, between January 1, 1980, and December 31, 2016, were reviewed to identify 78 incident SSc cases. The comparators were 156 sex- and age-matched individuals from the same population. Data for SSc characteristics, traditional CV risk factors, and CV events were collected. Cumulative incidence was adjusted for the competing risk for death.
RESULTS: During a median follow-up of 9.8 (SSc) and 9.2 years (non-SSc), 21 patients with SSc and 17 patients without SSc developed CV events, corresponding to 10-year cumulative incidence of 24.4% and 15.2%, respectively. The risk for incident CV disease was increased by 2-fold (hazard ratio, 2.38; 95% CI, 1.28-4.43) in patients with SSc vs comparators, predominately due to coronary artery disease (hazard ratio, 2.35; 95% CI, 1.17-4.71). Mean body mass index and prevalence of diabetes mellitus were lower in SSc vs non-SSc. There was no significant difference in smoking, hypertension, or hyperlipidemia. Observed CV events were increased compared with CV events predicted by the Framingham Risk Score and American College of Cardiology/American Heart Association score with standardized incident ratios of 4.16 (95% CI, 2.16-7.99) and 5.69 (95% CI, 2.71-11.94), respectively.
CONCLUSION: Patients with SSc are at >2-fold increased risk for experiencing a CV event compared with persons without SSc. Framingham Risk Score and American College of Cardiology/American Heart Association score dramatically underestimate CV risk in SSc.
Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32622445     DOI: 10.1016/j.mayocp.2019.12.015

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  4 in total

Review 1.  Heart Failure in Chronic Infectious and Inflammatory Conditions: Mechanistic Insights from Clinical Heterogeneity.

Authors:  Nour Beydoun; Matthew J Feinstein
Journal:  Curr Heart Fail Rep       Date:  2022-07-15

2.  Systemic Sclerosis Portends Increased Risk of Conduction and Rhythm Abnormalities at Diagnosis and During Disease Course: A US Population-Based Cohort.

Authors:  Yasser A Radwan; Reto D Kurmann; Avneek S Sandhu; Edward A El-Am; Cynthia S Crowson; Eric L Matteson; Thomas G Osborn; Kenneth J Warrington; Rekha Mankad; Ashima Makol
Journal:  J Scleroderma Relat Disord       Date:  2021-07-28

3.  CHLD score, a new score based on traditional risk factor evaluation and long-term cardiovascular outcomes in patients with systemic sclerosis.

Authors:  Klaudia Gieszczyk-Strózik; Maciej T Wybraniec; Małgorzata Widuchowska; Ligia Brzezińska-Wcisło; Przemysław Kotyla; Eugeniusz Kucharz; Katarzyna Mizia-Stec
Journal:  Sci Rep       Date:  2021-10-01       Impact factor: 4.379

Review 4.  Sclerodermic Cardiomyopathy-A State-of-the-Art Review.

Authors:  Adrian Giucă; Tea Gegenava; Carmen Marina Mihai; Ciprian Jurcuţ; Adrian Săftoiu; Diana Monica Gȋrniţă; Bogdan Alexandru Popescu; Nina Ajmone Marsan; Ruxandra Jurcuț
Journal:  Diagnostics (Basel)       Date:  2022-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.